Johnson & Johnson
HealthcareNYSE:JNJ · New York Stock Exchange
+$1.71 today
Vol 2.90M · Avg 7.84M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $21.7B |
| Short-term Investments | $363.0M |
| Receivables | $17.7B |
| Inventory | $14.6B |
| Other Current | $4.8B |
| Total Current Assets | $59.2B |
| PP&E (Net) | $54.7B |
| Goodwill | $48.6B |
| Intangible Assets | $49.1B |
| Tax Assets | $6.7B |
| Other Non-current | -$17.3B |
| Total Non-current Assets | $141.7B |
| Total Assets | $200.9B |
Analysis
Selected assets total $200.9B for Latest. The largest visible component is PP&E (Net) at $54.7B, about 27.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.7B -18.2% | $24.1B +10.3% | $21.9B +69.6% | $12.9B -11.0% | $14.5B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $393.0M -5.8% | $417.0M -61.0% | $1.1B -88.6% | $9.4B -45.1% | $17.1B | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $17.2B -9.2% | $18.9B +27.3% | $14.9B -12.1% | $16.9B -10.9% | $19.0B | $533.8M | $399.4M | -$1.7B |
| Inventory | $14.2B +14.0% | $12.4B +11.3% | $11.2B +8.9% | $10.3B -1.1% | $10.4B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $4.2B | $0 | $0 -100.0% | $5.8B +257.5% | -$3.7B | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $55.6B -0.5% | $55.9B +4.5% | $53.5B -3.3% | $55.3B -9.3% | $61.0B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $23.2B +12.9% | $20.5B +3.1% | $19.9B +10.7% | $18.0B -5.2% | $19.0B | $1.2B | $1.5B | $687.8M |
| Goodwill | $48.8B +10.3% | $44.2B +20.9% | $36.6B +1.4% | $36.0B +2.3% | $35.2B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $50.4B +34.0% | $37.6B +10.1% | $34.2B -11.2% | $38.5B -17.0% | $46.4B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $6.9B -34.3% | $10.5B +12.7% | $9.3B +3.7% | $8.9B -12.5% | $10.2B | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $14.4B +25.9% | $11.4B -19.4% | $14.2B -53.8% | $30.6B +199.7% | $10.2B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $143.6B +15.6% | $124.2B +8.9% | $114.1B -13.6% | $132.1B +9.1% | $121.0B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $199.2B +10.6% | $180.1B +7.5% | $167.6B -10.6% | $187.4B +2.9% | $182.0B | $13.3B | $11.9B | $10.6B |
| Account Payables | $12.0B +16.3% | $10.3B +7.0% | $9.6B -2.6% | $9.9B -10.5% | $11.1B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $8.5B +42.0% | $6.0B +73.4% | $3.5B -72.9% | $12.8B +238.7% | $3.8B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $3.8B +26.0% | $3.0B +34.8% | $2.2B +99.6% | $1.1B | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $0 -100.0% | $4.1B +3.3% | $4.0B -39.9% | $6.6B +85.1% | $3.6B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $54.1B +7.6% | $50.3B +8.7% | $46.3B -17.1% | $55.8B +23.4% | $45.2B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $39.4B +28.7% | $30.7B +18.4% | $25.9B -3.7% | $26.9B -10.3% | $30.0B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $6.8B +177.4% | $2.4B -23.3% | $3.2B -20.0% | $4.0B -46.7% | $7.5B | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $17.3B -31.3% | $25.2B +7.5% | $23.4B -2.0% | $23.9B -5.5% | $25.3B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $63.5B +9.0% | $58.3B +11.0% | $52.5B -4.1% | $54.8B -12.7% | $62.8B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $117.7B +8.3% | $108.6B +10.0% | $98.8B -10.7% | $110.6B +2.4% | $108.0B | $14.7B | $3.7B | $9.6B |
| Common Stock | $3.1B +0.0% | $3.1B +0.0% | $3.1B +0.0% | $3.1B +0.0% | $3.1B | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $169.0B +8.5% | $155.8B +1.3% | $153.8B +19.9% | $128.3B +4.3% | $123.1B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$14.9B -27.2% | -$11.7B +6.3% | -$12.5B +3.4% | -$13.0B +0.7% | -$13.1B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 +100.0% | -$153.8B -19.9% | -$128.3B -4.3% | -$123.1B | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $81.5B +14.1% | $71.5B +3.9% | $68.8B -10.5% | $76.8B +3.8% | $74.0B | $9.1B | $7.7B | $3.3B |
| Total Debt | $47.9B +30.8% | $36.6B +24.9% | $29.3B -26.0% | $39.6B +17.5% | $33.8B | $724.2M | $410.6M | $399.4M |
| Net Debt | $28.2B +125.3% | $12.5B +67.7% | $7.5B -72.1% | $26.8B +38.9% | $19.3B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
AbbVie Inc.
NYSE:ABBV
$401.42B
UnitedHealth Group Incorporated
NYSE:UNH
$370.46B
Merck & Co., Inc.
NYSE:MRK
$296.43B
Novartis AG
NYSE:NVS
$292.78B
AstraZeneca PLC
NYSE:AZN
$278.77B
Novo Nordisk A/S
NYSE:NVO
$196.35B
Amgen Inc.
NASDAQ:AMGN
$191.26B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.54B
Pfizer Inc.
NYSE:PFE
$149.33B
Sanofi
NASDAQ:SNY
$106.53B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does JNJ have?
Johnson & Johnson (JNJ) reported $19.71B in cash and equivalents in fiscal 2025.
How much debt does JNJ carry?
Johnson & Johnson (JNJ) reported $47.93B of total debt, with net debt of $28.22B.
Explore More
Continue the stock analysis
Jump to another research area for this company.